A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multiple Dose Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BMS-986263 in Adults With Advanced Hepatic Fibrosis After Virologic Cure of Hepatitis C
Phase of Trial: Phase II
Latest Information Update: 12 Dec 2019
Price : $35 *
At a glance
- Drugs BMS-986263 (Primary)
- Indications Hepatic fibrosis
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 09 Dec 2019 Status changed from recruiting to completed.
- 28 Feb 2018 Status changed from not yet recruiting to recruiting.
- 07 Feb 2018 New trial record